Incidence of lymphedema related to various cancers.
Cancer
Incidence
Long-term effects
Lymphedema
Oncology
Survivorship
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
accepted:
26
06
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Cancer-related lymphedema (CRL) lacks internationally accepted definition and diagnostic criteria. The accurate incidence of CRL is therefore a challenge and the condition is likely underreported. Patients treated for cancer can develop CRL as a result of surgery, chemotherapy, and/or radiotherapy, which can lead to considerable psychosocial and physical morbidity, and decreased quality of life. Determining CRL incidence is crucial to inform care access and resource allocation, to best support patients affected by this lifelong condition. This review aimed to provide the latest CRL incidence estimates. Using four core databases (MEDLINE, Embase, Web of Science Core Collection, Cochrane Library), a literature search was performed to capture publications dated between 2015 and 2023. A total of 48 articles (33 prospective studies, 15 systematic reviews) met inclusion criteria, providing a sample size of 234,079 cancer patients. Findings revealed CRL incidence across cancer types varied, reported 2-74% in breast, 8-45% in gynecological and urological, 71-90% in head and neck and 2-29% in melanoma cancers. CRL incidence varied between 3 and 21% in preventative lymphedema surgery patients. Projected increases in cancer incidence and improved survival rates are expected to further escalate CRL incidence. Healthcare systems and professionals alike must therefore prepare to meet the growing needs of CRL patients.
Identifiants
pubmed: 39289260
doi: 10.1007/s12032-024-02441-2
pii: 10.1007/s12032-024-02441-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Cancer. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer .
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - Survivorship (Version 1.2024). 2024–03–29]. Available from: https://www.nccn.org/guidelines .
Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett. 2023;10(1):451–451.
Neuman HB, Schumacher JR. Follow-up and cancer survivorship. Surg Clin. 2023;103(1):169–85.
Bowman C, Rockson SG. The role of inflammation in lymphedema: a narrative review of pathogenesis and opportunities for therapeutic intervention. Int J Mol Sci. 2024;25(7):3907.
pubmed: 38612716
pmcid: 11011271
Földi M et al., Földi's textbook of lymphology: for physicians and lymphedema therapists. Amsterdam: Elsevier Health Sciences; 2012.
Keast DH, Moffatt C, Janmohammad A. Lymphedema impact and prevalence international study: the Canadian data. Lymphat Res Biol. 2019;17(2):178–86.
pubmed: 30995190
pmcid: 6639111
Bowman C, Baydoun M, Carlson LE, The impact of cancer-related lower extremity lymphedema on patient quality of life: a qualitative meta-synthesis. J Psychosocial Oncol Res Pract. 2023. 5(2).
Cormier JN, et al. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138–49.
pubmed: 20665892
Jaszkul KM, et al. Global impact of lymphedema on quality of life and society. Eur J Plast Surg. 2023;46(6):901–13.
Forner-Cordero I, et al. Various clinical scenarios in secondary malignant lymphedema. Lymphology. 2022;55(4):144–54.
pubmed: 37553003
Stolldorf DP, Dietrich MS, Ridner SH. Symptom frequency, intensity, and distress in patients with lower limb lymphedema. Lymphat Res Biol. 2016;14(2):78–87.
pubmed: 26824629
pmcid: 4926205
Eaton L, Narkthong N, Hulett J. Psychosocial issues associated with breast cancer-related lymphedema: a literature review. Curr Breast Cancer Reports. 2020;12:216–24.
Roberson ML, et al. Financial burden of lymphedema hospitalizations in the United States. JAMA Oncol. 2021;7(4):630–2.
pubmed: 33599683
pmcid: 7893544
Boyages J, et al. Financial cost of lymphedema borne by women with breast cancer. Psychooncology. 2017;26(6):849–55.
pubmed: 27479170
Armer JM, et al. Lymphedema within the healthcare system. Lymphedema: A concise compendium of theory and practice. 2018;503–23.
Brown S, et al. Pharmacological treatment of secondary lymphedema. Front Pharmacol. 2022;13: 828513.
pubmed: 35145417
pmcid: 8822213
Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65(1):55–81.
pubmed: 25410402
CADTH Search Filters Database. 2023. Accessed: 2023-02-09. Available from: https://searchfilters.cadth.ca/link/35 .
Covidence systematic review software, M. Veritas Health Innovation, Australia. Available at https://www.covidence.org/
Moola S et al. Chapter 7: Systematic reviews of etiology and risk. JBI manual for evidence synthesis. JBI, 2020;10. Available online at: https://wiki.jbi.global/display/MANUAL
Munn Z, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implement. 2015;13(3):147–53.
Barker TH, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evi Syn. 2023;21(3):494–506.
Aromataris E, et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. JBI Evidence Implementation. 2015;13(3):132–40.
Armer JM, et al. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer. 2019;27:495–503.
pubmed: 29980907
Bundred N, et al. Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study. Br J Cancer. 2020;123(1):17–25.
pubmed: 32362658
pmcid: 7341763
Isik A, et al. Lymphedema after sentinel lymph node biopsy: who is at risk? Lymphat Res Biol. 2022;20(2):160–3.
pubmed: 34191608
Kilbreath SL, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast (Edinburgh, Scotland). 2016;28:29–36.
pubmed: 27183497
Kim M, et al. Breast cancer-related lymphedema after neoadjuvant chemotherapy. Cancer Res Treat. 2015;47(3):416–23.
pubmed: 25544575
Koelmeyer LA, et al. Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. Cancer. 2022;128(18):3408–15.
pubmed: 35797441
McDuff SGR, et al. Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys. 2019;103(1):62–70.
pubmed: 30165125
Miller CL, et al. Immediate implant reconstruction is associated with a reduced risk of lymphedema compared to mastectomy alone: a prospective cohort study. Ann Surg. 2016;263(2):399–405.
pubmed: 25607768
Naoum GE, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol Official J Am Soc Clin Oncol. 2020;38(29):3430–8.
Pereira A, Koifman RJ, Bergmann A. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast. 2017;36:67–73.
Salinas-Huertas S, et al. Risk factors for lymphedema after breast surgery: a prospective cohort study in the era of sentinel lymph node biopsy. Breast Dis. 2022;41(1):97–108.
pubmed: 34542055
Swaroop MN, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat. 2015;151(2):393–403.
pubmed: 25940996
pmcid: 4432026
Terada M, et al. Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. Breast Cancer Res Treat. 2020;179(1):91–100.
pubmed: 31535321
Wetzig N, et al. Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 2017;24:1064–70.
pubmed: 27848050
Zhu W, et al. Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema. Anticancer Drugs. 2017;28(3):350–5.
pubmed: 27997437
Bakri NAC, et al. Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients: a systematic review and meta-analysis. Ann Surg. 2023;277(4):572.
Gebruers N, et al. Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review. Arch Phys Med Rehabil. 2015;96(6):1131–9.
pubmed: 25637862
Lin Y, et al. Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis. Breast Cancer (Tokyo, Japan). 2021;28(6):1261–72.
pubmed: 34106427
Pilger TL, DF, Francisco FJ, Candido DR, Effect of sentinel lymph node biopsy on upper limb function in women with early breast cancer: a systematic review of clinical trials. Euro J Surg Oncol J Euro Soc Surg Oncol British Assoc Surg Oncol, 2021. 47(7):1497–506.
Rafn BS, et al. Prospective surveillance for breast cancer-related arm lymphedema: a systematic review and meta-analysis. J Clin Oncol Official J Am Soc Clin Oncol. 2022;40(9):1009–26.
Shah C, et al. The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements. Breast Cancer Res Treat. 2021;185(3):709–40.
pubmed: 33245458
Shaitelman SF, et al. Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2017;162(2):201–15.
pubmed: 28012086
Shen A, et al. Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies. Support Care Cancer. 2023;31(1):18.
Wu R, et al. Obese patients have higher risk of breast cancer-related lymphedema than overweight patients after breast cancer: a meta-analysis. Ann Transl Med. 2019;7(8):172.
pubmed: 31168453
pmcid: 6526274
Carlson JW, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol. 2020;156(2):467–74.
pubmed: 31837831
Cibula D et al. Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients. Cancers, 2021;13(10).
Geppert B, et al. Sentinel lymph node biopsy in endometrial cancer-feasibility, safety and lymphatic complications. Gynecol Oncol. 2018;148(3):491–8.
pubmed: 29273307
Hareyama H, et al. Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies. Int J Gynecol Cancer. 2015;25(4):751–7.
pubmed: 25723779
Hayes SC, et al. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol. 2017;146(3):623–9.
pubmed: 28624154
Ki EY et al., Incidence and risk factors of lower extremity lymphedema after gynecologic surgery in ovarian cancer. Int J Gynecol Cancer. 2016;26(7).
Mathevet P, et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: results of a multicentre randomised trial (SENTICOL-2). Eur J Cancer. 2021;148:307–15.
pubmed: 33773275
Pigott A, et al. Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study. Gynecol Oncol. 2020;158(2):375–81.
pubmed: 32499070
Ritchie J, et al. The frequency and persistence of lymphedema diagnosis and self-reported symptoms over 5 years in patients with endometrial carcinoma. Gynecol Oncol Reports. 2022;41: 100996.
Watson CH, et al. A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery. Gynecol Oncol. 2019;153(2):399–404.
pubmed: 30879878
Wedin M, et al. Incidence of lymphedema in the lower limbs and lymphocyst formation within one year of surgery for endometrial cancer: a prospective longitudinal multicenter study. Gynecol Oncol. 2020;159(1):201–8.
pubmed: 32763108
Clinckaert A, et al. The prevalence of lower limb and genital lymphedema after prostate cancer treatment: a systematic review. Cancers. 2022;14(22):5667.
pubmed: 36428759
pmcid: 9688147
Huang J, et al. Incidence of lower limb lymphedema after vulvar cancer: a systematic review and meta-analysis. Medicine. 2017;96(46): e8722.
pubmed: 29145314
pmcid: 5704859
Ridner SH, et al. A prospective study of the lymphedema and fibrosis continuum in patients with head and neck cancer. Lymphat Res Biol. 2016;14(4):198–205.
pubmed: 27305456
pmcid: 5178009
Tribius S, et al. Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy-results of a longitudinal study. Oral Oncol. 2020;109:104856.
pubmed: 32623355
Cromwell KD, et al. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care. 2015;24(5):724–33.
Morton RL, et al. Quality of life following sentinel node biopsy for primary cutaneous melanoma: health economic implications. Ann Surg Oncol. 2017;24(8):2071–9.
pubmed: 28321690
Nacchiero E et al. Multiple lymphatic-venous anastomoses in reducing the risk of lymphedema in melanoma patients undergoing complete lymph node dissection. A retrospective case-control study. J Plastic Reconstruct Aesthetic Surg JPRAS. 2019;72(4):642–8.
Gennaro M et al. Occurrence of breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: a two-arm randomized clinical trial. Cancer, 2022;128(24):4185–93.
Ozmen T, et al. Evaluation of simplified lymphatic microsurgical preventing healing approach (S-Lympha) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection. Ann Surg. 2019;270(6):1156–60.
pubmed: 29794843
Ciudad P, et al. Primary prevention of cancer-related lymphedema using preventive lymphatic surgery: systematic review and meta-analysis. Indian J Plast Surg Official Publi Assoc Plastic Surgeons Indiaia. 2022;55(1):18–25.
Co M, et al. Axillary reverse mapping in the prevention of lymphoedema: a systematic review and pooled analysis. Clin Breast Cancer. 2022;23(1):E14–9.
pubmed: 36384818
Johnson AR et al. Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann Plast Surg, 2019. 82(4S Suppl 3):S234–41.
Wijaya WA, et al. Clinical application of axillary reverse mapping in patients with breast cancer: a systematic review and meta-analysis. Breast. 2020;53:189–200.
pubmed: 32858404
pmcid: 7474002
Gursen C, et al. Self-reported signs and symptoms of secondary upper limb lymphoedema related to breast cancer treatment: systematic review. Eur J Cancer Care. 2021;30(5): e13440.